IL135211A0 - Diagnostic test for alzheimer's disease - Google Patents

Diagnostic test for alzheimer's disease

Info

Publication number
IL135211A0
IL135211A0 IL13521198A IL13521198A IL135211A0 IL 135211 A0 IL135211 A0 IL 135211A0 IL 13521198 A IL13521198 A IL 13521198A IL 13521198 A IL13521198 A IL 13521198A IL 135211 A0 IL135211 A0 IL 135211A0
Authority
IL
Israel
Prior art keywords
ache
glycosylation pattern
sample
alzheimer
disease
Prior art date
Application number
IL13521198A
Other languages
English (en)
Original Assignee
Univ Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Melbourne filed Critical Univ Melbourne
Publication of IL135211A0 publication Critical patent/IL135211A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/827—Actinoplanes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL13521198A 1997-09-24 1998-09-24 Diagnostic test for alzheimer's disease IL135211A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPO9432A AUPO943297A0 (en) 1997-09-24 1997-09-24 Diagnostic test for alzheimer's disease
PCT/AU1998/000809 WO1999015695A1 (en) 1997-09-24 1998-09-24 Diagnostic test for alzheimer's disease

Publications (1)

Publication Number Publication Date
IL135211A0 true IL135211A0 (en) 2001-05-20

Family

ID=3803714

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13521198A IL135211A0 (en) 1997-09-24 1998-09-24 Diagnostic test for alzheimer's disease

Country Status (11)

Country Link
US (1) US6461831B1 (cg-RX-API-DMAC7.html)
EP (1) EP1017845B1 (cg-RX-API-DMAC7.html)
JP (1) JP2001517456A (cg-RX-API-DMAC7.html)
AT (1) ATE323781T1 (cg-RX-API-DMAC7.html)
AU (1) AUPO943297A0 (cg-RX-API-DMAC7.html)
BR (1) BR9813015A (cg-RX-API-DMAC7.html)
CA (1) CA2304949A1 (cg-RX-API-DMAC7.html)
DE (1) DE69834263D1 (cg-RX-API-DMAC7.html)
HU (1) HUP0003684A3 (cg-RX-API-DMAC7.html)
IL (1) IL135211A0 (cg-RX-API-DMAC7.html)
WO (1) WO1999015695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL130225A0 (en) * 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20020150878A1 (en) * 2001-01-23 2002-10-17 Small David Henry Method for the diagnosis of Alzheimer's Disease and other prion related disorders
WO2004066808A2 (en) * 2002-12-20 2004-08-12 Momenta Pharmaceuticals, Inc. Glycan markers for diagnosing and monitoring disease
GB2404734A (en) * 2003-08-05 2005-02-09 Secr Defence A method of screening a sample for abnormally glycosylated and/or expressed proteins
US7598049B2 (en) * 2003-11-19 2009-10-06 Satoris, Inc. Methods for diagnosis of Alzheimer's Disease in blood samples
US20060094064A1 (en) * 2003-11-19 2006-05-04 Sandip Ray Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids
US20050272643A1 (en) * 2004-06-08 2005-12-08 Windber Research Institute Removal of serum albumin from human serum or plasma
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20100124756A1 (en) * 2008-10-10 2010-05-20 Sandip Ray Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US20110202284A1 (en) * 2010-02-10 2011-08-18 Mcreynolds Cristopher Novel groups of biomarkers for diagnosing alzheimer's disease
ES2395063B1 (es) * 2011-03-04 2014-02-07 Universidad Miguel Hernández De Elche Método para determinar la enfermedad de Alzheimer mediante la detección de glicoproteínas portadoras del glicoepítopo HNK-1
EP3255435A1 (en) 2012-04-13 2017-12-13 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595883A (en) * 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
CA2048700A1 (en) 1990-09-04 1992-03-05 Dasakumar S. Navaratnam Method for diagnosing senile dementia of the alzheimer type
US5200324A (en) * 1990-09-04 1993-04-06 E. R. Squibb & Sons, Inc. Method of diagnosing senile dementia of the Alzheimer type

Also Published As

Publication number Publication date
HUP0003684A3 (en) 2003-04-28
BR9813015A (pt) 2000-08-15
CA2304949A1 (en) 1999-04-01
JP2001517456A (ja) 2001-10-09
DE69834263D1 (de) 2006-05-24
ATE323781T1 (de) 2006-05-15
EP1017845A1 (en) 2000-07-12
AUPO943297A0 (en) 1997-10-16
US6461831B1 (en) 2002-10-08
HUP0003684A2 (hu) 2001-02-28
EP1017845B1 (en) 2006-04-19
EP1017845A4 (en) 2003-07-02
WO1999015695A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
AUPO943297A0 (en) Diagnostic test for alzheimer's disease
GB2380546A (en) Process for differential diagnosis of alzheimer's dementia and device therefor
ATE223051T1 (de) Verfahren zur diagnose gutartiger prostataerkrankungen
AU2001261741A1 (en) Diagnosis, prevention and treatment of crohn's disease using the ompc antigen
WO2002059604A8 (en) Diagnosis and treatment of multiple sclerosis
AU7635396A (en) Treatment and diagnosis of infections due to helicobacter pylori
CA2093928A1 (en) Monoclonal antibodies for detection and treatment of cancer
WO1996003502A3 (en) Muc1 derived proteins for the diagnosis, imaging and therapy of human cancer
ES2138729T3 (es) Metodos de diagnostico de la preeclampsia.
JP2001517456A5 (cg-RX-API-DMAC7.html)
WO1995005604A3 (en) Methods for the diagnosis of alzheimer's disease
ATE234466T1 (de) Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten
DE69333076D1 (de) Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis
ATE381346T1 (de) Assayverfahren für alzheimer-krankheit
WO2002041842A3 (en) Antibody pti-hs7 for treatment of alzheimer's disease and other amyloidoses and parkinson's disease
WO2001063293A8 (en) Diagnosis and treatment of schizophrenia
WO2002082077A3 (de) Herstellung polyklonaler, monospezifischer antikörper gegen die upar-varianten del4, del5 und del4+5 sowie deren verwendung für diagnostische und therapeutische zwecke
ATA19972000A (de) Pibf für die diagnose von tumoren
US20020177171A1 (en) Method and means for caries prevention and susceptibility detection
AU4098201A (en) Method for diagnosing efficacy of xenotypic antibody therapy
ATE209359T1 (de) Bestimmung von freiem und komplexiertem trypsinogen-2
UA10262A (uk) Спосіб ультразвукової діагностики стану судин головного мозку
Katelaris et al. Response to Dr. Laheijet al.
WO1999061918A1 (en) Method and means for caries prevention and susceptibility detection
UA33330A (uk) Спосіб діагностики ендогенної інтоксикації